Le Lézard
Classified in: Health
Subject: SVY

Anpac Bio Surpasses 50,000 Case Study Milestone



SACRAMENTO, Calif., Oct. 17, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Described as "game changing" and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or "Blood Biopsies", and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from the 50,000+ cases processed to date indicate Anpac Bio's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 75%-90% for over 26+ different types of cancer ? most at the disease's earliest stages.

The company has filed over 160 CDA-related patent applications worldwide ? 64+ issued currently; and maintains operations in six sites, employing over 100 people globally.

"Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand right now. We've processed over 50,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We're very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"

For more information about Anpac Bio please check: www.AnpacBio.com.

 

SOURCE Anpac Bio-Medical Science Company


These press releases may also interest you

at 21:59
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Plasma Protease C1-inhibitor Treatment Market: OverviewThis report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of...

at 21:37
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Ophthalmic Surgical Technologies Market: OverviewThe global ophthalmic surgical technologies market report provides a clear picture of the comprehensive dynamics of the market. The ophthalmic surgical...

at 21:21
LONDON, Nov. 20, 2017 /PRNewswire/ -- "Global tissue diagnostics market projected to grow at a CAGR of 6.9% during the forecast period" Download the full report: https://www.reportbuyer.com/product/5206184The tissue diagnostics market is expected to...

at 21:19
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Tattoo Removal Devices Market: OverviewThe report on the global tattoo removal devices market offers a critical evaluation of key factors and notable trends influencing the growth of the market. The study...

at 21:18
NEW YORK, Nov. 20, 2017 /PRNewswire/ -- Weight Watchers International, Inc. (NYSE: WTW) (the "Company") announced today that it has priced $300.0 million in aggregate principal amount of its 8.625% senior notes due 2025 (the "Notes") in a private...

at 21:17
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Stretch Marks Treatment Market: OverviewStretch marks also known as striae are commonly observed during or after pregnancy, during puberty, or a sudden change in weight. These marks appear due to the...




News published on 17 october 2017 at 07:30 and distributed by: